// App-Quantinova.ai

P263 : Should we advocate biologic dose-reduction in patients with AxSpA?

Researchers

Presenter

  • Liz Van Rossen

Principal Investigators

  • Cathal Boyle

  • Antoni Chan

  • Karl Gaffney

  • Annie Gilbert

  • Claire Harris

  • Pedro Machado

  • Santos Liliana

  • Raj Sengupta

  • Andrew Keat

Medical Centers

  • EKHUFT, Rheumatology, Whitstable, UNITED KINGDOM

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Rheumatology, Royal Berkshire Hospital, Reading, UNITED KINGDOM

  • Haematology, Norfolk and Norwich university hospitals, Norwich, UK

  • AK Gilbert, ltd, Brighton, UNITED KINGDOM

  • Rheumatology, Northwick Park, Whitstable, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved